Bleeding disorder is a set of diseases which normally affect the process of clotting of our blood. This bleeding can be in many cases like during an accident, trauma condition, surgery, injury or a menstrual cycle. These bleeding disorders are not only associated with bloods leaving out from our body, rather it can also be an internal bleeding beneath our skin or brain. These may be hemophilia A and B or Willebrand’s disease for example. Sometimes this disease is also termed as royal disease.
The main symptom of bleeding disorder would be excessive bleeding and prolonged clotting time during normal injuries also. These can also easily identified by frequent nose bleeding, heavy menstrual bleeding and unexplained bruishing.
There are mainly two common type of instant treatment available for bleeding disorder, which is iron supplementation or clotting factor repalacement and blood transfusion. These are the therapeutic aspect, but extended research is in progress in various countries, where this disease has a greater prevalence rate.
According to a recent study in Japan, the median age was 42.5 years (range, 17–55 years) in patients and 40.0 years (range, 25–55 years) in control subjects. Forty-six percent of patients had anemia; the median pictorial bleeding assessment chart score was 271. Seven percent of the control subjects with a subjectively normal menstruation had anemia. Twenty-six percent of patients had gynecologic abnormalities, which was considered to explain HMB. Overall, we found an underlying bleeding disorder in 29% of the patients, which was comparable for unexplained and explained HMB (31% vs 27%; P = .75). We diagnosed 6 cases of Von Willebrand's disease, 4 cases of factor XI deficiency, and 1 case of factor VII deficiency. The only abnormalities that we found in control subjects were platelet aggregation defects (11% in control subjects vs 23% in patients). Patients had a significantly longer activated partial thromboplastin time compared with control subjects (26.5 vs 25.0 seconds; P = .001) that was caused by lower median levels of factor XI (100 vs 124 IU/dL; P < .001).
Translational toolsas applicable to autoimmune disorders: antibody-proteases as a generation of highly informative and unique biomarkersto monitor subclinical and clinical stages of demyelination in multiple sclerosis (MS) PPT Version |